HIV disease is often perceived as a condition affecting young adults. However, approximately 11% of new infections occur in adults aged 50 years or older. Among persons living with HIV disease, it is estimated that more than half will be aged 50 years or older in the near future. In this review, we highlight issues related to HIV prevention and treatment for HIV-uninfected and HIV-infected older Americans, and outline unique considerations and emerging challenges for public health and patient management in these 2 populations. (Am J Public Health. 2012;102:1516–1526. doi:10.2105/AJPH.2012.300844)

The Centers for Disease Control and Prevention (CDC) estimates that 10.8% of the roughly 50 000 incident HIV infections that occur annually in the United States are among persons aged 50 years or older and that, among persons newly diagnosed with HIV infection in 2010, the median age was 35 to 39 years and 16.5% were aged 50 years or older. In high-prevalence areas, HIV infection has been present in up to 5% of persons who died older than 60 years.

Continued Risk for Older HIV-Uninfected Adults

Although sexual activity declines with age, the majority of Americans aged 57 to 65 years and a substantial fraction aged 66 years or older remain sexually active, including persons who are HIV-infected. The reasons why older Americans continue to become infected with HIV have not been extensively researched, but the phenomenon is likely multifactorial. Older persons, who may include persons who have been recently widowed or divorced after having been in a long-term monogamous relationship, have a poor understanding of their risk for a disease that they often perceive as affecting predominately young people or gay men. Furthermore, only a minority of patients aged 50 years and older report having discussed sexual activity with their care providers. Conversely, care providers are generally poor at routinely collecting and recording sexual histories of their patients, particularly for patients aged 50 years or older, possibly because they perceive older patients to be at low risk, they fear insulting or angering an older patient, or because they are personally uncomfortable discussing sexual activity with a person who is the age of their parents or grandparents.

Despite sexual activity and risk for HIV infection, few older Americans use condoms to protect themselves from infection during sexual intercourse. According to the 2008 National Survey of Sexual Health and Behavior, among all persons aged 50 years or older, condoms were not used during most recent intercourse with 91.5% of casual partners, 76.0% of friends, 69.6% of new acquaintances, and 33.3% of transactional sexual partners.

Postmenopausal women who no longer require birth control to prevent pregnancy may not consider the need for condoms during intercourse. The decreased levels of circulating estrogen following menopause lead to a thinner vaginal epithelium and decreased mucus production, making these tissues more susceptible to microabrasions that could facilitate HIV infection. Recent data suggest that the postmenopausal cervix may undergo immune changes that also favor HIV acquisition; these tissues become more enriched with target cells (i.e., CD4+ and CCR5+ T cells) and produce greater amounts of inflammatory factors that favor HIV replication. For older men, the availability of erectile dysfunction medications through both prescription and nonprescription sources and easier access to sexual intercourse, including commercial sexual intercourse, through the Internet and social media, may facilitate capacity for and access to sexual activity.

HIV Testing for Elderly Persons

For the purpose of this review, older refers to persons aged 50 years and older and elderly to persons aged 65 years and older. The CDC has recommended universal opt-out HIV testing of all persons aged 13 to 64 years accessing health care services in private or public settings to reduce the number of HIV-infected Americans who are unaware of their HIV status, and to enable linkage of these persons to HIV care and prevention services. Current CDC guidelines do not recommend universal opt-out testing for persons aged 65 years and older, an age group in which HIV prevalence is currently below the threshold at which generalized screening would be considered cost-effective, in part because of the excess costs incurred by the greater proportion of falsely negative tests. However, this recommendation does not mean that all elderly persons are at low risk. As illustrated previously, many persons aged 50 years or older engage in behaviors that place them at risk for HIV infection.

As the cohort of persons living with HIV ages (see the “Adults Aging With HIV Infection” section), the percentage of HIV-infected adults aged 65 years or older may become large enough to justify universal HIV opt-out testing of this age group. At present, testing persons in this age group should be based on clinical judgment after a thorough assessment of risk including sexual activity, number and types of sexual partners (i.e., commercial sex worker, same-sex partner), and other potential risk factors. All persons, regardless of age, should be tested for HIV before initiating a new sexual relationship. Aging HIV-negative men who have sex with men who continue to have high-risk sexual exposures with HIV-infected partners, may be considered for preexposure prophylaxis.
HIV Risk-Reduction Programs for HIV-Uninfected Older Adults

The need for effective prevention programs for persons aged 50 years and older has been repeatedly recognized, including at a White House summit on HIV and aging in October 2010. Although no national prevention programs designed specifically for older Americans were listed in the most recent 2009 national inventory, a program has been developed by the Administration on Aging (http://www.aoa.gov/AoARoot/AoA_Programs/HPW/HIV_AIDS/index.aspx) that includes fact sheets, posters (Figure 1), customizable PowerPoint templates, and an educational video. Additional campaigns have been created by special interest groups, such as “HIV Wisdom for Older Women” (http://www.hivwisdom.org/bio.html), “Services and Advocacy for Gay, Lesbian, Bisexual and Transgender Elders” (http://sageusa.org/index.cfm), and Safer Sex for Seniors (http://safersex4seniors.org). Local jurisdictions with large numbers of older persons have also created programs such as the Senior HIV Intervention Project in Broward County, Florida, and the AIDS Community Research Initiative of America (http://www.acria.org; Figure 1) and Gay Men’s Health Crisis (http://www.gmhc.org), which are both based in New York City. Innovative national programs aimed at adults aged 50 years or older have also been started in other countries, such as Brazil, where a campaign aimed at older adults has been linked to important national events such as Carnaval (http://www.aids.gov.br/campanha/carnaval-2009) or the World Cup soccer championship (http://www.aids.gov.br/campanha/dia-mundial-de-luta-contra-aids-2008; Figure 1).

Adults Aging With HIV Infection

The increasingly longer survival afforded by highly active combination antiretroviral therapy (cART) and ongoing new infections among persons older than 50 years (close to 5400 per year or 10.8% of all new infections from 2006 to 2009) are steadily shifting the demographic profile of the US HIV epidemic toward older age groups. CDC estimated that in 2009 persons aged 50 years and older constituted 33% of all persons living with HIV infection in the 46 states with confidential name-based HIV infection reporting (Figure 2).
Late HIV diagnoses and poorer prognosis among persons diagnosed at an older age are also reflected in the national HIV surveillance data. In the 46 states with long-established confidential name-based reporting of HIV infections to CDC, 14% of persons younger than 25 years diagnosed with HIV infection during 2009 progressed to AIDS in 1 year compared with 42% of persons aged 50 to 54 years, 45% of persons aged 55 to 59 years, and 49% of persons aged 60 years or older (Figure 4). Furthermore, survival declined with age at diagnosis, whether diagnosed with HIV infection or AIDS. For instance, 3-year survival for persons younger than 25 years diagnosed with either outcome was equal to or greater than 95% compared with 82% and 75%, respectively, for persons aged 50 to 54 years, 78% and 71% for persons aged 55 to 59 years, and 73% and 66% for persons aged 60 years or older (Figure 5).

Inferior Responses to Antiretroviral Therapy in Elderly

Persons who are newly diagnosed with HIV infection, including those aged 50 years and older, should be offered HIV antiretroviral therapy regardless of CD4 cell count. Older patients may adhere better to antiretroviral therapy but appear equally likely to achieve virologic suppression compared with younger patients. Nonetheless, older patients with suppressed HIV RNA viral loads consistently experience less robust CD4 count responses, most likely because CD4 cell-mediated immune reconstitution depends on thymic function, which decreases with age. Response in older patients also does not appear to vary whether the regimen used is protease inhibitor–based or non–nucleoside reverse transcriptase inhibitor–based. Treatment guidelines now recommend initiating antiretroviral therapy immediately after HIV diagnosis regardless of CD4 cell count for all older patients, but further research is needed to inform preferred regimens for this age group. Important issues include selecting regimens with a minimal number of toxicities and reviewing comprehensively other medical conditions and medications to minimize drug–drug interactions.

Burden of Select Chronic Illnesses Among HIV-Infected Patients

As HIV-infected adults live longer, they are increasingly affected by a number of chronic illnesses that are also common in the general population but that seem to occur at rates greater than expected for age. These conditions include cardiovascular disease, renal and hepatic disorders, osteopenia and bone fractures, endocrine and metabolic abnormalities (e.g., lipodystrophy or abnormal fat redistribution, metabolic syndrome), and certain non–AIDS-defining cancers (e.g., liver, lung, anal). As rates of these conditions have increased, there has been a remarkable coincident shift in the predominant causes of death from AIDS-related opportunistic illnesses to non–AIDS-related causes, in particular hepatic cirrhosis, renal failure, cardiovascular events (e.g., myocardial infarction, stroke), and malignancy. Apart from the expected contribution of normal aging, 3 additional sets of factors contribute to risk, to varying degrees and often in complex interplay: (1) factors associated directly with chronic HIV infection including viral replication and attendant inflammation, (2) toxicities and other complications of treatment with antiretroviral agents, and (3) host-related factors that are especially prevalent among HIV-infected adults, including certain coinfections (e.g., human papillomavirus, hepatitis B); and lifestyle factors (e.g., alcohol and tobacco use, obesity; Figure 6). We will highlight select conditions that commonly affect aging HIV-infected patients in the United States.

Cardiovascular disease. HIV-infected patients have greater 10-year risk of cardiovascular events and higher rates of atherosclerosis than HIV-uninfected persons. The landmark international Strategies for Management of Antiretroviral Therapy study demonstrated definitively that episodic untreated HIV replication and consequent immune activation and inflammatory responses were associated with elevated risk not only of death from any cause (hazard ratio [HR] = 2.6; 95% confidence interval [CI] = 1.9, 3.7) but notably (and unexpectedly at the time) of incident major cardiovascular, renal, and hepatic disease (HR = 1.7; 95% CI = 1.1, 2.5). Subsequent research has confirmed that HIV infection itself is associated with greater risk of atherosclerosis independent of viral load, type of antiretroviral therapy, or extent of immunodeficiency. However, whether HIV infection is itself truly an important risk factor for cardiovascular disease that can be modified by treatment remains controversial; randomized clinical trial data are
lacking and the best existing data come from observational cohort studies that must be interpreted cautiously. 

Antiretroviral treatment and the extent of immunodeficiency can also alter cardiovascular risk. Certain antiretrovirals alter lipid metabolism creating an atherogenic cholesterol profile; these and other antiretrovirals (e.g., abacavir) may also have additional but as yet unidentified effects that increase risk for acute coronary syndrome. A low CD4 cell count has been found to be an independent risk factor for cardiovascular disease comparable in attributable risk to several traditional risk factors (e.g., male gender, low high-density lipoprotein, 

Note: In 2007, the median age was 40-44 years, and 28.6% were aged ≥ 50 years. In 2009, the median age was 45-49 years, and 32.7% were aged ≥ 50 years.

FIGURE 2—Estimated numbers of persons living with HIV, by year and selected characteristics in (a) 2007 and (b) 2009: 46 states with confidential name-based reporting of HIV infections to the Centers for Disease Control and Prevention.

FIGURE 3—Median CD4 cell count, and the proportion of individuals who have a CD4 cell count greater than or equal to 350 cells/mm³, at first presentation for HIV clinical care in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).
There is accumulating evidence that the increase in risk conferred by exposure to certain antiretroviral medications (most notably, the protease inhibitors) is generally moderate compared with the risk conferred by traditional demographic (e.g., age, sex, and race) and modifiable risk factors (e.g., smoking, obesity, and hypertension), as well as by HIV itself. In the Data Collection on Adverse Events of Anti-HIV Drugs study of more than 23,000 patients followed during 1999 to 2005, for instance, the adjusted relative rate of myocardial infarction per year of protease inhibitor exposure was 1.10 (95% CI = 1.04, 1.18), compared with 1.32 (95% CI = 1.23, 1.41) per 5 years of age but 2.92 (95% CI = 2.04, 4.18) for current tobacco smoking.

Although HIV and its treatment likely contribute to cardiovascular disease risk, the largest contributors remain modifiable lifestyle factors and treatable chronic comorbidities. Estimated tobacco smoking rates among HIV-infected US adults since 2000 have ranged from 47% to 70% compared with rates of less than 25% in the general population. Increasing attention has been focused on smoking cessation programs tailored for this high-risk group. Increasing attention has also been drawn to the high prevalences among HIV-infected patients of dyslipidemia and metabolic syndrome, which predispose to cardiovascular disease and type 2 diabetes. Lastly, since the advent of effective therapy, the prevalence of obesity among HIV-infected persons has steadily increased. For a disease hallmarked originally by wasting, overweight and obese patients now often outnumber underweight patients in many clinical settings.

**Bone health.** Low bone mineral density (BMD) is remarkably prevalent among HIV-infected adults; up to 60% have been estimated to have osteopenia and up to 15% osteoporosis, rates that are much higher than for demographically matched non-HIV-infected patients. HIV-infected adults also experience higher rates of fragility fractures than comparable non–HIV-infected adults after adjustment for known risk for bone fracture including older age, illicit substance use, and hepatitis C coinfection. Among HIV-infected patients, those who have experienced greater immunosuppression, defined as a nadir CD4 cell count less than 200 cells/mm³, experienced rates of fracture 60% greater than patients who had never been severely immunosuppressed. A causal relationship between low BMD and greater fracture risk has yet to be established, and no research has yet addressed the population benefit of routine BMD assessment, treatment of low BMD, and whether assessment of BMD when aged younger than 50 years might be warranted for HIV-infected adults. Some experts have advocated conducting BMD assessments for patients with fragility fractures, all HIV-infected postmenopausal women, and all HIV-infected men aged 50 years and older.

![Graph showing percentage of persons alive at 36 months by type of diagnosis: 46 states with confidential name-based HIV infection reporting, 2009.](image1)

**FIGURE 5**—Percentage of persons alive at 36 months by type of diagnosis: 46 states with confidential name-based HIV infection reporting, 2009.
Considering that risk for and frequency of falls increases substantially with age, research is needed to address how and when best to screen for and correct reversible causes of low BMD and fall risk for HIV-infected patients in routine care.

Cancers. An increasing number of HIV-infected persons are experiencing non–AIDS-defining cancers that typically occur at older ages. A large US study has documented that in a demographically diverse national cohort of 55,000 HIV-infected patients during 1992 through 2003, compared with the general population of similar demographics, the incidence of the following non–AIDS-defining cancers was higher among HIV-infected persons: anal, vaginal, Hodgkin’s lymphoma, liver, lung, melanoma, oropharyngeal, leukemia, colorectal, and renal. Compared with non–HIV-infected counterparts, HIV-infected persons are at particular risk for cancers with a known infectious cause, although this higher risk has decreased in the antiretroviral therapy era. A national study by Shiels et al. documented substantial increases in non–AIDS-defining cancers among HIV-infected persons over a 15-year period (1991–2005); whereas counts of AIDS-defining cancers decreased, non–AIDS-defining cancers increased by approximately threefold (3193 to 10,059 cancers; P for trend < .001) and were mainly driven by growth and aging of the HIV-infected population afforded in large part to effective antiretroviral therapy. Notably, an examination of 212,055 persons with AIDS enrolled in the US HIV/AIDS Cancer Match Study from 1996 to 2007 revealed that, after adjustment for differences in the populations at risk, the median ages at cancer diagnosis among persons with AIDS (i.e., only persons with the most advanced stage of HIV disease) and persons in the general population did not differ for most types of cancer (e.g., colon, prostate, or breast cancer). By contrast, ages at diagnosis of lung cancer (median = 50 vs 54 years) and anal cancer (median = 42 vs 45 years) were significantly younger in persons with AIDS than expected in the general population (P < .001). Although the appearance of most cancers in HIV-infected persons may not be actually occurring at younger-than-expected ages, a growing burden of non–AIDS-defining cancers in the aging HIV-infected population requires targeted cancer prevention and treatment strategies. In addition to aspects of HIV infection that may be amenable to treatment (e.g., immunodeficiency, inflammatory responses to chronic viremia), associated preventable or treatable viral coinfections (e.g., human papillomavirus, hepatitis B and C) and preventable lifestyle factors traditionally associated with cancer (e.g., tobacco smoking, alcohol use, obesity) contribute to patients’ risk of non–AIDS-defining malignancies.

Frailty. Frailty is a late-stage clinical syndrome associated with adverse health outcomes, including mortality. Frailty is characterized by multiple pathologies, including weakness, low physical activity, and slow motor performance. This geriatric syndrome also occurs among HIV-infected persons, albeit at a younger age. Among men followed in the Multicenter AIDS Cohort Study, prevalence of the frailty-related phenotype for 55-year-old men infected with HIV for 4 years or less (3.4%; 95% CI = 1.3, 8.6) was similar to that of uninfected men aged 65 years and older (3.4%; 95% CI = 1.5, 7.6). This phenotype was associated with increased duration of HIV infection, markers of advanced immunodeficiency, comorbidity, and negative clinical outcomes, and subsided upon immunologic restoration related to treatment with cART. Analyses from the Veterans Aging Cohort Study have found that, across the age groups, decline in physical function per year was greater in HIV-infected patients than in uninfected patients, but this difference was modest. A study of 455 HIV-infected persons with a median age of 41.7 years (71% male, 63% Black, with a mean 8.4 years since HIV diagnosis, 75% on cART with median CD4 of 437 cells/mm³) found that the frequency of frailty (defined by presence of at least 3 of 5 criteria: weight loss, low physical activity, exhaustion, weak grip strength, and slow walking time) was 9%, substantially higher than would be expected for this age group. Factors associated with frailty in that study included unemployment, greater number of comorbid conditions and past opportunistic illnesses, and higher depression severity score; hospitalization rates were greater and inpatient stays 5-fold longer for frail persons compared with non-frail persons.

Psychiatric and Neurocognitive Conditions. HIV-infected patients experience a higher frequency of neurocognitive and psychiatric problems, including depression, than do age-matched HIV-negative controls, even after adjusting for contributory sociodemographic and behavioral risk factors (e.g., alcohol and drug use) that are known to be more prevalent among HIV-infected persons. Although psychiatric illness can increase the risk of HIV acquisition, in most cases HIV is probably not causally related to psychiatric illness, such as through direct...
effects of the virus on the central nervous system. Living with a chronic, life-threatening, and highly stigmatized illness can exacerbate or trigger thought and mood disorders. Regular screening for psychiatric illness, especially depression, is therefore an important part of comprehensive HIV care. Depression is not only the most common psychiatric condition affecting HIV-infected adults, among whom it is remarkably underrecognized and undertreated, but both depressive symptoms and suicide are also most frequent among older persons, especially the elderly aged 65 years and older.

Use of cART has been shown to restore neurocognitive performance in HIV-infected women, although a history of profound immunosuppression ( nadir CD4 cell count < 200 cells/mm³) and inflammatory state may have persistent effects on neurocognitive impairment among patients in the cART era. Treatment of depression in HIV-infected patients correlates with improvements in antiretroviral medication adherence, virologic responses, and survival.

**Whether HIV Infection Accelerates Aging**

“Accelerated” or “precocious” aging are terms often used to describe the appearance of conditions that traditionally affect older persons at a younger than expected age. Whether HIV infection accelerates aging remains an open question. As noted previously, a growing number of comorbid medical conditions seem to be more common in HIV-infected patients, and both these conditions and their biological precursors may occur among HIV-infected persons at younger ages than would be expected. However, rather than directly mediating (i.e., accelerating) the aging process, HIV infection may simply contribute to increasing the frequency and severity of chronic diseases as do other independent risk factors (e.g., tobacco smoking or poor diet), and thus lead to increased prevalence of these conditions among HIV-infected patients compared with uninfected controls of the same age. In addition, the HIV-infected population in the United States is enriched in patients with sociodemographic risk factors that predispose to chronic diseases, such as male gender, non-White race/ethnicity, and poverty, as well as tobacco and alcohol use. If comparisons are made of HIV-infected persons to persons from the general population without controlling for differences in the prevalence of such risk factors, then it is possible that the age of onset for certain conditions (e.g., cardiovascular disease) could appear precocious. Furthermore, as elegantly shown by Shiels et al., the observation that certain conditions associated with aging, such as cancer, appear to affect HIV-infected adults at younger ages than adults in the general population may be an artifact of different age structures of the 2 populations.

It is interesting that HIV infection impairs the function of the immune system in many of the same ways as aging. The hallmark of HIV infection is its persistent destruction of CD4+ T cells that progressively depletes the immune system’s capacity to carry out effective immunosurveillance. As reviewed recently by Effros et al., aging—like HIV infection—is also associated with B cell dysfunction (most notably the inability to produce effective antibody responses), thymus involution, and decreases in the number of naïve T cells (both CD4+ and CD8+), and T-cell hyporesponsiveness and eventual replicative senescence.

The strongest evidence for an association between HIV infection and acceleration of the aging process comes from studies of immunosenescence and immune activation. For example, in a recent analysis from the Women’s Interagency HIV Study, HIV-associated T-cell changes (including higher frequencies of activated CD4+ and CD8+ T cells and immunosenescent CD8+ T cells) were associated with subclinical carotid artery abnormalities, even among patients achieving viral suppression with effective cART. These emergent and compelling basic science data will be important to consider as we design future studies to examine how and why the manifestation of certain comorbidities may differ between HIV-infected and non–HIV-infected adults as they age.

**Toxicity of Antiretroviral Therapy and Polypharmacy**

To date, there have been relatively few data on drug-drug interactions with non-HIV medications and short- and long-term toxicity and tolerability of antiretrovirals in older HIV-infected adults. Because many randomized controlled trials evaluating new antiretroviral drugs or chemoprophylaxis of HIV-related complications excluded patients with either advanced age or comorbidities, there are few pharmacokinetic data for persons at the extremes of age. A recent analysis of tipranavir use in relation to the risk of intracranial hemorrhage found that increasing age was a risk factor for such hemorrhage, and an expanded-access study found that age was a risk factor for changes in serum creatinine level in patients on tenofovir. Older age is associated with a high rate of adverse events from pharmacologic agents; therefore, careful monitoring is essential when one is using antiretrovirals and medications to prevent and to treat opportunistic illness in older HIV-infected patients.

Of note, HIV-infected patients with renal or hepatic insufficiency deserve special attention when certain antiretroviral drugs are used. Both

---

**Importance of Primary and Preventive Care**

For patients who are effectively retained in HIV care, the recommended frequency of medical encounters (typically 2 to 4 times yearly) offers repeated opportunities for preventive care, including brief messages regarding the importance of smoking cessation, exercise and dietary modifications, and other lifestyle changes to prevent or better manage various chronic diseases. Routine age-appropriate cancer screenings (e.g., mammography, colonoscopy, cervical Papanicolaou tests) as well as screening for and treatment of cardiovascular disease according to guidelines need to be ensured. Additional research is needed to inform guidelines development regarding the value of earlier or more intensive screening for certain types of cancer (e.g., anal cancer) and low BMD. A significant fraction of HIV-infected patients die from violent and accidental causes related to drug abuse and poor mental health, underscoring the importance of connecting patients to ancillary mental health, substance abuse, and case-management services.

Middle- and older adults living with HIV may lack community support, typically lack siblings or parents to care for them, and may have experienced multiple AIDS-related losses within their social networks. Case management and integrated care can help them confront the physical and psychosocial aspects of the disease and reduce marginalization and the dual stigma of both aging and HIV.
renal and hepatic injury are more common among older individuals with HIV, especially among older individuals with histories of heavy drug or alcohol use.110 Tenofovir and indinavir have nephrotoxic potential.111 In addition, tenofovir, which must be dose-adjusted based on estimated creatinine clearance (i.e., reduced dosage with reduced clearance), may be more likely to cause complications in elderly patients who have lower creatinine clearance than younger patients. Some protease inhibitors and non-nucleoside reverse transcriptase inhibitors can exacerbate hepatic insufficiency in persons with preexisting liver disease; however, there is little information on how to adjust dosages of these drugs in older patients with impaired renal or hepatic clearance.

Pharmacologic interactions between antiretroviral agents and other drugs used in the elderly are common. Extensive review of all medications prescribed by all medical providers (including over-the-counter medications), such as through medication therapy management by a pharmacist familiar with HIV care, may reduce the risk of drug–drug interactions. For example, proton pump inhibitors, which are commonly used in patients with dyspepsia, are contraindicated with atazanavir because they decrease gastrointestinal absorption of this protease inhibitor. In addition, concomitant use of benzodiazepines and protease inhibitors can result in excessive sedation. Therapeutic drug monitoring may be useful in patients who are at high risk for adverse events.

PUBLIC HEALTH NEED AND OPTIONS FOR ACTION

With regard to elderly non–HIV-infected persons, the key take-home messages for the general practitioner include:

• Improve behavioral risk assessment.
• Improve coordination of primary and complex subspecialty care.
• Remember to continue age-appropriate preventative screenings.
• Incorporate HIV prevention (e.g., brief risk assessment, risk-reduction counseling, testing for sexually transmitted disease) into routine HIV care to prevent ongoing HIV transmission.

The key messages for the public health practitioner include increasing awareness about the risk for HIV infection and the importance of its early diagnosis and treatment among older adults and among their caregivers.

Despite evidence that aging Americans remain sexually active and account for about 11% of incident HIV infections each year, many may not perceive themselves as at risk for HIV infection despite unsafe sexual behavior, which often goes unmentioned or unaddressed in interactions with their primary care providers. Health care and service providers on all levels should be educated on HIV risk behaviors and symptoms of HIV infection (both acute infection and advanced HIV illness); they need to conduct thorough sexual and drug-use risk assessments with their older clients and offer both routine HIV screening14,15,112 and diagnostic HIV testing, as warranted. The CDC recommends routine voluntary HIV screening for all persons aged 13 to 64 years without regard to risk in all health care settings where the prevalence of undiagnosed HIV infection is 0.1% or more; HIV testing of persons aged 65 years and older may be considered based on risk history.14 Health departments and community-based organizations in jurisdictions with more than rare cases of HIV and sexually transmitted diseases among older and elderly adults should consider systematic outreach and educational programs to provide seniors with accurate information about the relevance of HIV/AIDS to their lives. Programs aimed at reaching general health practitioners (e.g., opportunities for licensure-related accredited education) should cover clinical vigilance for, testing for, and diagnosis of HIV infection, and the importance of ensuring timely linkage of newly HIV-diagnosed persons to specialty HIV care.

With regard to elderly HIV-infected persons, the key take-home messages for a general practitioner include:

• Improve coordination of primary and complex subspecialty care.
• Remember to continue age-appropriate preventative screenings.
• Incorporate HIV prevention (e.g., brief risk assessment, risk-reduction counseling, testing for sexually transmitted disease) into routine HIV care to prevent ongoing HIV transmission.

The key messages for the public health practitioner include developing a surveillance and research agenda to better characterize the clinical epidemiology of chronic HIV infection in persons aged 50 years and older, and determining appropriate thresholds for general preventative screening practices (e.g., bone densitometry, colorectal cancer assessment) tailored to persons with chronic HIV infection.

In the pre- and early cART era, HIV-infected patients mostly succumbed to opportunistic illnesses and were cared for chiefly by infectious disease practitioners. As mentioned before, a large proportion of today’s patients are living with and being hospitalized for traditionally non–HIV-related chronic medical conditions and have a greater likelihood of death from these causes than from AIDS.44,46,47 As HIV-infected patients age and experience multiple comorbidities, the integration of HIV care and primary care becomes ever more important.104 HIV providers should be comfortable with standard chronic disease management and coordinate care with specialists as needed (e.g., cardiologists, nephrologists, oncologists). Programs aimed at reaching general health practitioners should cover the importance of ensuring linkage of newly HIV-diagnosed persons to specialty HIV care and attention to coordination of primary and complex subspecialty care that older HIV-infected patients often require. Finally, primary care providers should engage their HIV-infected patients in discussions of sexual health, to encourage HIV disclosure and condom use to prevent HIV transmission to sexual partners. Programs such as Ask–Screen–Intervene (http://depts.washington.edu/nmpc/online_training/asi) and Prevention IS Care (http://www.actagainstaids.org/promote/pic/index.html) are brief provider-driven prevention interventions developed to provide clinicians practical tools they can integrate into their daily practice to help their HIV-infected adult patients reduce the risk of transmitting HIV to others and to maintain sexual health. National guidelines for incorporating HIV prevention into the medical care of persons living with HIV infection first published in 2003112 are undergoing revision; these guidelines are a valuable resource for clinicians and public health practitioners seeking a broader set of constructive and specific recommendations about best practices.

About the Authors

John T. Brooks, Kate Buchacz, and Jonathan Mermin are with the Centers for Disease Control and Prevention (CDC), Atlanta, GA. Kelly A. Gebo is with the Johns Hopkins School of Medicine, Baltimore, MD.
Correspondence should be sent to John T. Brooks, Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, 1600 Clifton Rd NE, Mailstop E-45, Atlanta, GA 30333 (e-mail: z4dh@cdc.gov). Reprints can be ordered at http://www.aphl.org by clicking the "Reprints" link.

This article was accepted April 3, 2012.

Note. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC.

Contributors
All authors contributed to the origination, design, analysis, and interpretation of data; drafted and revised the content; and approved the final version to be published.

Acknowledgments
This article was prepared for the CDC series on aging and the roles of public health.

Human Participant Protection
Human participant protection was not required because no human participants were involved.

References


In the HAART era, the prevalence and incidence of neurocognitive impairment have been significantly reduced. Robertson et al. (2001) reported that the treatment with highly active antiretroviral therapy (HAART) has led to a reduction in the prevalence of neurocognitive impairment (NCI) in HIV-infected individuals. Harezlak et al. (2011) found that persistence of adherence to highly active antiretroviral therapy (ART) in HIV-infected women was associated with better cognitive performance.

Cohen et al. (2012) observed that the use of ART was associated with enhanced performance on neuropsychological tests. However, researchers have also found that ART can have adverse effects on cognitive function, such as impaired memory and concentration. Harezlak et al. (2011) found that ART use was associated with increased risk of intracranial hemorrhage.


Effros et al. (2009) identified several factors that may contribute to the development of cognitive impairment in HIV-positive patients, including neurotoxicity, HIV progression, and comorbidity of aging. They suggested that further research is needed to understand the role of these factors in the development of cognitive impairment.


Cohen et al. (2012) also highlighted the importance of monitoring and managing cognitive impairment in HIV-positive patients. They emphasized the need for early detection and intervention to prevent further cognitive decline.


In conclusion, the treatment with HAART has significantly reduced the prevalence and incidence of neurocognitive impairment in HIV-infected individuals. However, researchers need to continue to study the long-term effects of ART on cognitive function and develop strategies to mitigate these effects.

Cohen et al. (2012) concluded that further research is needed to understand the complex relationship between HIV infection, ART, and cognitive function. They emphasized the importance of early detection and intervention to prevent further cognitive decline in HIV-positive patients.